These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 17518814

  • 1. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
    Encephale; 2005 Jun; 31(2):235-46. PubMed ID: 15959450
    [Abstract] [Full Text] [Related]

  • 3. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.
    Pharmacoeconomics; 2005 Jun; 23 Suppl 1():35-47. PubMed ID: 16416760
    [Abstract] [Full Text] [Related]

  • 4. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G, Heeg B, van Hout BA, Mehnert A.
    Pharmacoeconomics; 2005 Jun; 23 Suppl 1():49-61. PubMed ID: 16416761
    [Abstract] [Full Text] [Related]

  • 5. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB.
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [Abstract] [Full Text] [Related]

  • 6. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.
    Value Health; 2004 Oct; 7(1):22-35. PubMed ID: 14720128
    [Abstract] [Full Text] [Related]

  • 7. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of olanzapine and risperidone in Norway.
    Kim K, Aas E.
    J Ment Health Policy Econ; 2011 Sep; 14(3):125-35. PubMed ID: 22116170
    [Abstract] [Full Text] [Related]

  • 9. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N, Foster RH, Olney R, Plosker GL.
    Drugs; 2001 Sep; 61(1):111-61. PubMed ID: 11217867
    [Abstract] [Full Text] [Related]

  • 10. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [Abstract] [Full Text] [Related]

  • 11. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [Abstract] [Full Text] [Related]

  • 12. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
    Palmer CS, Brunner E, Ruíz-Flores LG, Paez-Agraz F, Revicki DA.
    Arch Med Res; 2002 Aug; 33(6):572-80. PubMed ID: 12505105
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR.
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [Abstract] [Full Text] [Related]

  • 14. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S, O'Donnell O.
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.
    Pharmacoeconomics; 2005 Apr; 23 Suppl 1():75-89. PubMed ID: 16416763
    [Abstract] [Full Text] [Related]

  • 16. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
    Dilla T, Prieto L, Ciudad A, Sacristán JA.
    Actas Esp Psiquiatr; 2004 Apr; 32(5):269-79. PubMed ID: 15529211
    [Abstract] [Full Text] [Related]

  • 17. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
    Lindner LM, Marasciulo AC, Farias MR, Grohs GE.
    Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
    [Abstract] [Full Text] [Related]

  • 18. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D, Moisan J, Abdous B, Grégoire JP.
    Can J Clin Pharmacol; 2008 Aug; 15(3):e385-97. PubMed ID: 18953083
    [Abstract] [Full Text] [Related]

  • 19. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR, Maia-Lopes S, Goswami P, Bereza BG, Van Impe K.
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [Abstract] [Full Text] [Related]

  • 20. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.